Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer
Colorectal cancer with peritoneal metastases is currently treated by cytoreductive surgery and locoregional chemotherapeutics. This standard treatment is associated with high morbidity, mortality, and recurrence rate. To augment the existing therapy, we developed a liposome-based delivery system con...
Saved in:
Main Authors: | Griffin Pauli (Author), Po-Han Chao (Author), Zhu Qin (Author), Roland Böttger (Author), Suen Ern Lee (Author), Shyh-Dar Li (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds
by: Griffin Pauli, et al.
Published: (2019) -
A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod
by: Zhongkun Zhang, et al.
Published: (2021) -
Detection of tumor‐derived cell‐free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid
by: Iris van't Erve, et al.
Published: (2021) -
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin
by: Pascale C. S. Rietveld, et al.
Published: (2024) -
Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
by: Supreeda Tambunlertchai, et al.
Published: (2022)